CSafe and BioLife Solutions Partnership Will Expand Supply Chain for Cell and Gene Therapies

CSafe, a US-based provider of active and passive temperature-controlled shipping solutions, and BioLife Solutions, a US-based supplier of bioproduction tools and services for the cell and gene therapy (CGT) and broader biopharma markets, have formed a new partnership to provide a combined global service network to support CGT products. The partnership will focus on enhanced reliability, security, and quality, according to an Oct. 11, 2022 company press release.

BioLife expects to support 10,000–12,000 shipments of CGT starting materials and manufactured doses over the next 12 months using its evo cold chain management platform. The new partnership with CSafe will provide BioLife with expanded supply chain options for any CGT product at any stage of development, from early clinical-phase trials to global commercial scale. CSafe operates more than 50 service centers worldwide.

“CSafe is honored to partner with the team at BioLife Solutions, whose range of CGT bioproduction tools and services is peerless in the market. We are excited to merge these exceptional tools and services with our expertise in global, reliable scaled delivery,” said CSafe CEO Patrick Schafer in the press release. “CGT is hitting its stride and needs global support. We know how important these therapies are to patients everywhere, and it’s our mission at CSafe to protect every shipment.”

“We’re excited to work with a global partner with a strong history of reliability and performance and a deep dedication to innovative therapies,” said BioLife Solutions CEO Mike Rice in the release. “We have the best LN2 [liquid nitrogen] technology and [C]GMP [current good manufacturing practice] storage facilities in the market, in addition to our other world-class CGT solutions, and we are confident our collaboration with CSafe will extend our reach and result in even more reliability and real-time service for CGT partners.”

Source: CSafe